



Unaudited Financial Statements

Isla Rose Foundation
For the year ended 31 January 2024

Prepared by Kirkwood Wilson Limited



Contents

3	Trustees Report
5	Trustees
6	Independent Examiner's Report
7	Income & Expenditure Account
8	Balance Sheet

Trustees Report

Isla Rose Foundation

For the year ended 31 January 2024

Isla Rose Foundation - Yearly Update (2024)

Making a Difference Together

We're thrilled to share the Isla Rose Foundation's achievements this year!

Key Achievements in 2023:

- **Funding Research:** We made a significant contribution of £3,000 to support vital NKH research at UCL London.
- **Supporting Families:** We directly impacted a young girl's life by funding three months of specialised therapy for Sofia, battling NKH.

Fundraising Success:

Despite a challenging economic climate, the Southport community and supporters beyond have rallied behind us. We've successfully raised funds through local and national press coverage, alongside heartwarming community fundraising events.

Raising Awareness:

Social media continues to be a powerful tool. By sharing our journey, we've significantly increased awareness of NKH's rarity and garnered invaluable support from the wider community.

Our Vision:

- A cure for NKH remains our ultimate goal.
- We'll continue to empower NKH families by providing access to equipment and therapies not readily available through the NHS, ultimately improving their quality of life.

Research Progress: Gene Therapy for NKH Shows Promise

Gene therapy research using mice models is demonstrating significant advancements, offering a glimmer of hope for improved treatment of Non-Ketotic Hyperglycinemia (NKH). This approach holds exciting potential for:

- **In-utero Treatment:** Early intervention is crucial, and gene therapy offers the possibility of treating NKH before birth, potentially preventing the severe complications often associated with the disease.
- **Extended Lifespans:** Current treatments manage symptoms but are not curative. Gene therapy has the potential to address the underlying genetic cause, potentially leading to a significant improvement in lifespan and overall well-being for NKH patients.

Success Rate Improvements:

While research is still in pre-clinical stages, studies in mice models have shown promising results:

- **Increased Activity of the Functional Enzyme:** Gene therapy successfully introduces a healthy copy of the affected gene, leading to the production of the functional enzyme responsible for glycine breakdown. This directly addresses the core issue in NKH.
- **Reduced Glycine Levels:** Studies report a significant decrease in glycine levels in treated mice, indicating the potential to control the toxic buildup associated with the disease.
- **Improved Neurological Function:** Early intervention through in-utero gene therapy has shown promise in theory of preventing the severe neurological complications often seen in NKH patients.

Challenges and Opportunities:

While fundraising remains competitive, our daughter's story has garnered significant local and national media attention, raising awareness and vital funds. In the future, we plan to rent equipment to therapy centres, with proceeds benefiting the foundation.

Opportunities YouTube channel or increasing awareness of social media pages.



Our Five-Year Goals:

- Secure maximum funding to find a cure for NKH.
- Empower NKH families with grants for therapy, equipment, and essential support.
- Increase research funding at UCL.
- Look into opening a local charity shop/pop up shop trial to potentially bring in constant funding support without setting up actual events.

Values and Collaboration

Collaboration is at the heart of our success. We value:

- Community support and involvement in fundraising initiatives.
- Seeking professional free guidance to refine our goals and research efforts.
- Continuous learning and a commitment to progress.
- Supporting everyone affected by NKH - families, researchers, and fundraisers.

We operate with a dedicated team of volunteers who are passionate about our cause.

Financial Sustainability:

The Isla Rose Foundation operates independently through our website. Generous volunteer accountants manage our yearly accounts.

Future Plans:

Our board of trustees meets quarterly to review progress and strategically plan for the future. We ensure our actions align with our core values and effectively manage any risks.

We continue as a non profit and don't charge expenses.



Trustees

Isla Rose Foundation

For the year ended 31 January 2024

Trustees

The trustees are responsible for the management of the risks faced by the Charity.

S.J, Steel - Chair

S J, Carney - Trustee

Bankers

NatWest Bank PLC

130 Lord Street, Southport

PR9 0AE


Independent Examiner


Kirkwood Wilson Limited

Unit 2A, Swordfish Business Park, Burcough

L40 8JW

Authorised and approved on behalf of the Trustees.

X Signed  Date 2.7.24

X Signed  Date 2.7.24



Independent Examiner's Report

Isla Rose Foundation

For the year ended 31 January 2024

Independent Examiner's Report to the trustees of the Isla Rose Foundation

We report on the accounts of the Charity for the year ended 31 January 2024, which are set out on pages 7 and 8.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is our responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to our attention.

Basis of independent examiner's report

Our examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts give a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with our examination, no matter has come to our attention:

1. which gives us reasonable cause to believe that in any material respect the requirements to keep accounting records in accordance with section 130 of the 2011 Act; and to prepare accounts with the accounting records and comply with the accounting requirements of the 2011 Act have not been met; or
2. to which, in our opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Independent Examiner

Signed: Kirkwood Wilson Ltd

Date: 2/7/24

Kirkwood Wilson Limited Unit 2A, Swordfish Business Park, Lancashire, L40 8JW



Income & Expenditure Account

Isla Rose Foundation

For the year ended 31 January 2024

2024

Income and Expenditure Account

Donations Received	30,545
Therapy & Equipment Expenses	(10,208)
Donations Made	(3,000)
Total Income and Expenditure Account	17,336



Balance Sheet

Isla Rose Foundation
As at 31 January 2024

31 JAN 2024

Assets (liabilities)

Assets less current liabilities

Current Account	24,925
Total Assets less current liabilities	24,925

Total Assets (liabilities)	24,925
----------------------------	--------

Capital and reserves

Total Profit & Loss

Current Year Earnings	17,336
Profit and loss account	7,589
Total Total Profit & Loss	24,925

Total Capital and reserves	24,925
----------------------------	--------

A handwritten signature in dark ink, consisting of several fluid, overlapping loops and strokes, located in the lower-left quadrant of the page.